Apr 6 2012
Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical
laboratory and cardiovascular disease management company, today
announced that its panel of inflammation biomarkers will be featured at
next week's TEDMED 2012 conference in Washington. The annual conference,
being held April 10-13, explores the issues, challenges and innovations
that are shaping the future of health and medicine.
Conference participants may choose to receive inflammation testing that
uses CHL's proprietary biomarkers and the company's advanced approach to
inflammation. The degree of inflammation in one's arteries is a better
predictor of heart attack and stroke than cholesterol or other testing
alone.
"We are thrilled to be participating in TEDMED 2012 and highlighting our
advanced approach to assessing cardiovascular disease risk," said Jake
Orville, president and chief executive of CHL. "Our test panels offer
broader prognostic coverage than traditional blood tests, enabling a
determination of the degree to which someone is at risk for
cardiovascular disease. TEDMED 2012, with its focus on health care
innovation that drives systemic improvement, is an outstanding platform
from which to highlight our approach and we are grateful for the
opportunity."
The company also said it will launch a new campaign focused on
inflammation testing next week. The campaign will seek to raise
awareness of inflammation testing and its importance with physicians,
nurses and other health care professionals, and patients.
Source: Cleveland HeartLab
Daily walnut snacks fail to lower inflammation in adults